Eosinophilia during Psoriasis Treatment with TNF Antagonists (original) (raw)

Eosinophilic cellulitis (Wells' syndrome) as a cutaneous reaction to the administration of adalimumab

Ioanna Lefaki

Annals of the Rheumatic Diseases, 2006

View PDFchevron_right

Paradoxical psoriatic arthritis in a patient with psoriasis treated with ustekinumab: Table 1

Daniela Marasović Krstulović

Rheumatology, 2015

View PDFchevron_right

Eosinophils, pruritus and psoriasis: effects of treatment with etretinate or cyclosporin-A

Rudolf Schopf

Journal of the European Academy of Dermatology and Venereology, 1998

View PDFchevron_right

PRACTITIONER ’ S CORNER Subacute Prurigo and Eosinophilia in a Patient With Rheumatoid Arthritis Receiving Infl iximab and Etanercept

N. Cancelliere

2011

View PDFchevron_right

Subacute prurigo and eosinophilia in a patient with rheumatoid arthritis receiving infliximab and etanercept

N. Cancelliere

Journal of investigational allergology & clinical immunology, 2011

View PDFchevron_right

Tocilizumab-Induced Drug Reaction With Eosinophilia and Systemic Symptoms Syndrome in Adult-Onset Still Disease: A Case Report

Anita Lee

Annals of internal medicine, 2017

View PDFchevron_right

Efalizumab in the treatment of psoriasis: when comorbidity is an issue

Francesca Prignano

Dermatologic Therapy, 2008

View PDFchevron_right

The Role of Benralizumab in Eosinophilic Immune Dysfunctions: A Case Report-Based Literature Review

Ana Mendes

Case Reports in Medicine

View PDFchevron_right

Severe Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms Overlap Syndrome Treated with Benralizumab: A Case Report

Patrick Bader

Case Reports in Dermatology, 2022

View PDFchevron_right

Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases

Yannick Elshot

Melanoma Research, 2023

View PDFchevron_right

Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis

Franck Delesalle

Arthritis and Rheumatism, 2008

View PDFchevron_right

Adverse reactions of biological therapies in patients with psoriasis

ALEXANDRA LIMBAU

Journal of Mind and Medical Sciences, 2017

View PDFchevron_right

Psoriasiform dermatitis in a non-psoriatic patient treated with adalimumab

B. Laganà

International journal of immunopathology and pharmacology

View PDFchevron_right

Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab

Yu-min Kuo

Journal of Clinical Pharmacy and Therapeutics, 2008

View PDFchevron_right

Mepolizumab as a steroid-sparing treatment option in a patient with eosinophilic granulomatosis with polyangiitis

Ana Rita Presa

Arquivos de Asmas Alergia e Imunologia, 2021

View PDFchevron_right

Wells syndrome in a patient receiving adalimumab biosimilar: A case 18. Chiriac A, Brzezinski P, Stolnicu S, Podoleanu C, Moldovan C, Molnar C, et al. Eosinophilia – A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis. J Dermatolog Treat 2016;27:110-3. r...

Bishandas Radotra

Indian Journal of Dermatology, Venereology and Leprology, 2018

View PDFchevron_right

Rapid recovery of postnivolumab vemurafenib-induced Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome after tocilizumab and infliximab administration

Davide Zanon

Journal for ImmunoTherapy of Cancer

View PDFchevron_right

Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis

Susanna Bormioli

Allergy, Asthma & Immunology Research

View PDFchevron_right

Eosinophilic annular erythema showing eosinophil cytolytic ETosis successfully treated with benralizumab

Katsunori Masaki

Asia Pacific Allergy, 2021

View PDFchevron_right

Paradoxical Reaction to Golimumab: Tumor Necrosis Factor a Inhibitor Inducing Psoriasis Pustulosa

Rachel Grynszpan

Case Reports in Dermatology, 2013

View PDFchevron_right

Lack of Anti-drug Antibodies in Patients with Psoriasis Well-controlled on Long-term Treatment with Tumour Necrosis Factor Inhibitors

C. Zachariae

Acta Dermato Venereologica, 2012

View PDFchevron_right

Efalizumab in Psoriasis: Our Experience with 11 Patients~!2010-01-28~!2010-05-10~!2010-06-11~!

Aurora Guerra

The Open Dermatology Journal, 2010

View PDFchevron_right

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS): Is cutaneous phenotype a prognostic marker for outcome? A review of clinicopathological features of 27 cases

Salvador J Diaz-Cano

British Journal of Dermatology

View PDFchevron_right

A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents

Francisco Tausk

Annals of the Rheumatic Diseases, 2006

View PDFchevron_right

Adverse reactions of biological therapy for psoriasis

Andreea Dimitriu

2015

View PDFchevron_right

Adalimumab induced severe paradoxical psoriasis in a patient with ankylosing spondylitis

Pınar Karabağlı

Cukurova Medical Journal, 2022

View PDFchevron_right

Efalizumab-Associated Papular Psoriasis

Saad Hassan

Archives of Dermatology, 2007

View PDFchevron_right

Psoriasiform Reactions to Anti–Tumor Necrosis Factor α Therapy

Khang Nguyễn

Journal of Clinical Rheumatology, 2013

View PDFchevron_right